Polidocanol foam sclerotherapy is a new and effective treatment for post-operative lymphorrhea and lymphocele
Polidocanol foam sclerotherapy is a new and effective treatment for post-operative lymphorrhea and lymphocele
复制标题
DOI：
10.1111/j.1468-3083.2009.03546.x
复制
发表时间：
2010-08-01
影响因子：
9.2
通讯作者：
Dissemond, J.
中科院分区：
文献类型：
--
作者：
Klode, J.;Kloetgen, K.;Dissemond, J.
背景：淋巴结手术后淋巴囊肿和淋巴漏的形成是一个潜在的严重并发症。到目前为止，对于这些并发症的最有效治疗方法还没有达成共识。因此，我们的临床试验的目的是比较使用聚多卡因醇泡沫硬化疗法与压迫疗法的伤口引流，在治疗术后淋巴囊肿。患者和方法回顾性分析了2004年至2008年间33例连续发生术后淋巴囊肿的手术患者的资料。我们对所有患者进行引流加压治疗或聚多醇泡沫硬化治疗1天，以治疗术后淋巴囊肿。结果12例患者采用聚多醇泡沫硬化治疗，21例患者单独引流。分泌量从最初的50-350 ml/天下降到治疗结束时的0-20 ml/天。接受聚多卡因醇泡沫硬化治疗的患者（中位4天，平均6.4天）比接受引流治疗的患者（中位31天，平均30.2天）的淋巴分泌缓解速度快得多（P < 0.0001）。所有患者均未出现严重并发症。结论聚多醇泡沫硬化疗法是治疗淋巴细胞术后患者的一种有效且耐受性良好的新疗法。
BackgroundThe formation of post-operative lymphocele and lymphorrhea following lymph node surgery is a potentially serious complication. Until now there has been no consensus on the most effective treatment for these complications. Therefore, the aim of our clinical trial was to compare the use of polidocanol foam sclerotherapy with compression therapy to wound drainage, in the treatment of post-operative lymphoceles.Patients and methodsRetrospectively we analysed the data of 33 consecutive surgical patients who had developed a post-operative lymphocele between 2004 and 2008. We offered all patients drainage with compression therapy or polidocanol foam sclerotherapy with 1-day compression to treat the post-operative lymphoceles.ResultsAltogether, 12 patients were treated with polidocanol foam sclerotherapy and 21 patients were treated with drainage alone. Secretion volumes declined from initial 50-350 ml/day to 0-20 ml/day at the end of the therapy. Lymphorrhea resolved much quicker (P < 0.0001) in patients treated with polidocanol foam sclerotherapy (median 4 days, mean value 6.4 days) than in those treated with drainage (median 31 days, mean value 30.2 days). None of the patients developed a major complication.ConclusionPolidocanol foam sclerotherapy is an effective and well-tolerated new treatment for patients with post-operative lymphoceles.